Fig F-FGln shows uptake in human gliomas undergoing progression.

Slides:

Advertisements

Similar presentations

Change in longest diameter = -19%. Change in sum of perpendicular diameters = -21%

Advertisements

Radiotherapy treatment planning and long-term follow-up with [11C]methionine PET in patients with low-grade astrocytoma Joanne Nuutinen, M.D., Pirkko.

Coronal PET-CT scans in an 18-yr-old woman performed 6 mo apart.

Volume 21, Issue 4, Pages xv-xxiii (December 1998)

How I treat extramedullary myeloma

PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma Kemp H Kernstine, MD, PhD, William Stanford, MD, Brian F Mullan,

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Jenny Dave, MS, Mark A. Ahlman, MD, Benjamin N. Lockshin, MD, David A

Examples of functional imaging biomarkers in two DCA responders

Fig. 4. Primary human metastatic melanomas contain CCL21-expressing LECs, and expression of VEGFC positively correlates with hallmarks of tumor inflammation.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 3. Copy number loss as a potential resistance mechanism in an independent cohort. Copy number loss as a potential resistance mechanism in an independent.

Fig. 1. A 24-year-old male with a malignant germ cell tumor in the anterior mediastinum. (A) Coronal contrast-enhanced CT image shows a lobulated hypoattenuating.

Fig. 1. [11C]Martinostat images of all subjects show high cortical binding and distinct gray-white matter differences. [11C]Martinostat images of all subjects.

Fig. 2. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral blood. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 4 Infection-induced CLV dysfunction is associated with decreased LMC coverage. Infection-induced CLV dysfunction is associated with decreased LMC.

Intravenous delivery of reovirus to primary and secondary brain tumors

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Fig. 6. Effects of CD31-NP targeting in perfused human kidneys.

Figure 4 11C-PK11195-PET scans showing the evolution of neuroinflammation in a patient after stroke Figure 4 | 11C-PK11195-PET scans showing the evolution.

Fig. 4. Specific versus nonspecific NP accumulation.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Type 1 immunity drives metabolic disease but protects against NAFLD

Fig. 5. Clinical data with BLU-285 confirm early evidence of activity in patients with diseases driven by KIT and PDGFRA activation loop mutations. Clinical.

Fig. 2 In vitro assessment of hESC-RPE cell sheets.

Fig. 2. Best model fits. Best model fits. Illustration of the best model fits for the (A) basic, (B) continuous, and (C) cluster models. See Table 1 and.

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Pharmacodynamic effects of PI3K inhibitor NVP-BKM120 on breast carcinomas in MMTV-CreBrca1f/fTrp53+/− mice. Pharmacodynamic effects of PI3K inhibitor NVP-BKM120.

Representative CT and PET/CT images of three patients with NSCLCs

Fig. 1 Double-raster plot demonstrating the timing of sleep in the chronic sleep loss and control protocols Double-raster plot demonstrating the timing.

Fig. 7. KIF11 informs patient prognosis, and targeting improves survival in a preclinical model. KIF11 informs patient prognosis, and targeting improves.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by.

False-positive findings at the base of the left pterygoid process on conventional CT images alone in a 63-year-old woman with nasopharyngeal carcinoma.

Junjie Zhang et al. JACEP 2017;3:

Henry Chubb et al. JACEP 2017;3:89-103

Fig. 6. Rolling neutrophils extract membranes from fragile remnant PS+ platelets. Rolling neutrophils extract membranes from fragile remnant PS+ platelets.

Fig. 6. Heterogeneous A1R and GIRK1/4 protein expression in human SAN and atria revealed by ex vivo molecular mapping. Heterogeneous A1R and GIRK1/4 protein.

Fig. 2. SRS and traditional microscopy of intrinsic brain tumors.

Fig. 2 In vitro and preclinical study with 18F-MPG.

Fig. 1 CSPG4 is expressed in GBM specimens and GBM-NS and associated with more aggressive disease. CSPG4 is expressed in GBM specimens and GBM-NS and associated.

Evaluation of clinical responses after infusion of CART19 cells

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 2 LAEs are characterized by vascular dysfunction, loss of endothelial perfusion and permeability, and perivascular hypoxia. LAEs are characterized.

Fig. 6 Photoreceptor cell survival in the RCS rat retina after transplantation with hESC-RPE cell sheets. Photoreceptor cell survival in the RCS rat retina.

Correlation of reovirus RNA/protein with proliferating tumor cells

Fig. 5. Rises in RSV PRNT during the surveillance period.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 4 DMI visualizes the Warburg effect in a patient with GBM after oral [6,6′-2H2]glucose intake. DMI visualizes the Warburg effect in a patient with.

Fig. 7. Analysis of dFMRP kinetics in dFMRP granules by FRAP

Fig. 2. Bacterial/viral score in COCONUT-conormalized whole-blood validation data sets. Bacterial/viral score in COCONUT-conormalized whole-blood validation.

Fig. 1. Brain imaging before surgery

Fig. 3 Imaging-guided S-HDL nanoimmunotherapy in rabbits and pigs: PET-based readouts. Imaging-guided S-HDL nanoimmunotherapy in rabbits and pigs: PET-based.

Representative CT and PET/CT images of three patients with NSCLCs

TL maps and multiple biopsies in a 71-year-old patient with primary GBM. TL-based color map overlay on a T2-weighted image (A) shows predicted regional.

Axial contrast-enhanced CT demonstrates a myocutaneous fat flap (white arrow) used for reconstruction following resection of a squamous cell carcinoma.

Evaluation of clinical responses after infusion of CART19 cells

CT scans and data analysis obtained from patient 1

Noninvasive detection of acquired MET amplification as a mechanism of afatinib/trastuzumab resistance using cfDNA. Noninvasive detection of acquired MET.

Fig. 2 In vitro and preclinical study with 18F-MPG.

Change in FES uptake in the tumor during fulvestrant treatment.

Representative quantitative maps of a patient with brain metastasis.

Fig. 2. MRI shows an irregularly shaped, 4. 9 × 4

Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses. Schematic description of whole-exome or targeted next-generation.

Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.

False-positive findings at the base of the left pterygoid process on conventional CT images alone in a 63-year-old woman with nasopharyngeal carcinoma.

Presentation transcript:

Fig. 5. 18F-FGln shows uptake in human gliomas undergoing progression. 18F-FGln shows uptake in human gliomas undergoing progression.(A to F) Images from patient #5. (A) T1-weighted MRI with contrast enhancement from a 42-year-old IDH1m oligodendroglioma patient showing tumor with minimal gadolinium enhancement (red arrows) along surgical cavity (indicated by white dotted line). (B) Fusion 18F-FGln PET-CT showing 18F-FGln uptake in areas corresponding to tumor (red arrows). (C) 18F-FDG PET image from the same patient showing high background brain avidity and tumor uptake in the posterior part of the tumor (three red arrows), but not in the anterior portion (two red arrows). (D) CT scan used to generate the PET-CT fusion image in (B). (E) 18F-FGln PET showing high uptake in tumor with minimal uptake in the surrounding brain. (F) Time-activity curve indicating standard uptake values (SUV) corresponding to tumor (black squares) and blood (clear circles). (G to K) Images from patient #6. (G) T1-weighted MRI with contrast enhancement from a 57-year-old GBM patient showing tumor with gadolinium enhancement (red arrows). (H) Fusion 18F-FGln PET-CT showing 18F-FGln uptake in areas corresponding to tumor. (I) 18F-FDG PET image from same patient showing high background brain avidity and tumor uptake. (J) CT scan used to generate the PET-CT fusion image in (H). (K) 18F-FGln PET showing high uptake in tumor with minimal uptake in the surrounding brain. (L) Comparison of 18F-FGln (blue bars) and 18F-FDG (red bars) illustrates differences in background uptake with both ligands in normal brain (top panel) and tumor-to-brain ratios from three clinically stable glioma patients and three glioma patients with clinically progressive disease (bottom panel) (see tables S1 and S2 for details). For all graphs, data are represented as means ± SEM. Sriram Venneti et al., Sci Transl Med 2015;7:274ra17 Published by AAAS